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ABSTRACT 
Molecular hybridization is a ligand based drug design approach is well known recent medicinal 
chemistry to design anti-parasitic agents. In the present study, we have designed a series of (1-
phenyl-9H-pyrido[3,4-b]indol-3-yl)(4-phenylpiperazin-1-yl)methanone derivatives using 
molecular hybridization approach. Designed analogues were evaluated for cytotoxicity and 
inhibition activity against Leishmania infantum and Leishmania donovani. Among these reported 
analogues 7b, 7d, 7e, 7f and 7m displayed potent inhibition of both L. infantum and L. donovani. 
Compounds 7i and 7k exhibited selective potent inhibition of L. donovani. Especially, 
compounds 7e and 7k showed most potent anti-leishmanial activity against L. infantum and L. 
donovani respectively. Anti-leishmanial activity of these compounds is comparable with 
standard drugs miltefosine and pentamidine. SAR studies revealed that, electron donating group 
substitution on phenyl ring recommended for potent anti-leishmanial activity. 
Keywords: Molecular hybridization, β-carboline, anti-leishmanial activity, Leishmania 
infantum, Leishmania donovani 
1. Introduction 
Leishmaniasis is one of the most neglected diseases, caused by protozoan parasite Leishmania 
spp. and is present throughout the tropics and sub-tropics, putting a fifth of the world’s 
population at risk [1]. Leishmaniasis has been classified into Cutaneous Leishmaniasis (CL), 
Mucocutaneous Leishmaniasis (MCL), Visceral Leishmaniasis (VL) and post-kala-azar dermal 
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leishmaniasis (PKDL) [2]. Among these, visceral Leishmaniasis is considered as severe form and 
is caused by Leishmania donovani and Leishmania infantum. Visceral leishmaniasis affects 
internal organs such as bone marrow, liver, and spleen [3]. Un-fortunately, treatment of 
leishmaniasis is dependent upon very old drugs such as antimonials. Pentavalent antimonials 
such as sodium stibogluconate and meglumine antimoniate have been used for more than 60 
years, however increasing incidence of resistance has been reported. Despite of its adverse 
effects, Amphotericin B is the drug of choice, where antimonial resistance is prevalent. Second 
line drugs such as diamidine, pentamidine and paromomycin have limited use in leishmaniasis 
chemotherapy [4, 5]. Miltefosine is the only oral anti-leishmanial drug that has been approved by 
FDA / WHO to date [6]. Miltefosine has restricted use in pregnancy and high risk of resistance 
due to long half-life (150 h). Clinical efficacy of miltefosine has been decreasing in countries 
like India, where it is used extensively [7]. Hence, there is an urgent need of new anti-
leishmanial agents with better therapeutic profiles. 
β-Carbolines and derivatives thereof have a privileged position in medicinal chemistry, with 
diverse biological activity spectrum, such as, anti-malarial [8, 9], anti-leishmanial [10-12], anti-
tubercular [13], anti-bacterial [14], anti-viral [15-17], anti-cancer [18] and anti-thrombotic [19]. 
Natural β-carboline alkaloids such as, harmine [20], buchtienine [11], annomontine [21] and 
manzamine A (Fig. 1) displayed potent anti-leishmanial activity. Manzamine a group  of β-
carboline alkaloids, have exhibited significant anti-leishmanial activity [22] and we recently 
published a review on their anti-leishmanial activity [23]. In addition to these natural alkaloids, 
large number of synthetic β-carboline derivatives also display potent anti-leishmanial activity. 
Synthetic β-carboline derivatives with substitution on position 1, 2, 3 and 9 of β-carboline 
skeleton have shown significant anti-leishmanial activity [24-26]. Piperazine moiety is well 
known in medicinal chemistry, to be the second most prevalent heterocyclic ring present in all 
FDA approved drugs up to 2013 [27]. Piperazine derivatives exhibited wide range of biological 
activities including anti-bacterial [28, 29], anti-protozoal [30, 31], anti-leishmanial [32], anti-
tubercular, anti-viral [33] and anti-cancer [34] activities (Fig. 1). This is especially true for 
bisarylpiperazine derivatives (two different heterocyclic rings attached to piperazine scaffold) 
which show potent anti-leishmanial activity [35, 36]. Based upon these collective facts and 
through a molecular hybridization approach, we have designed a new series of β-carboline and 
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piperazine hybrid molecules (Fig. 1). In the present study, design, synthesis and anti-leishmanial 
activity of piperazinyl-β-carboline derivatives have been reported. 
 
Fig. 1. Structure of reported and designed β-carboline-piperazine hybrid molecules 
2. Results and Discussion 
2.1. Chemistry 
The synthetic protocol of the reported 1-phenyl-9H-pyrido[3,4-b]indole-3-carboxamide 
derivatives is illustrated in scheme 1. The compounds were synthesized in a sequence of 
reactions using DL-Tryptophan (1) as starting material. Initially DL-Tryptophan (1) was 
converted to DL-tryptophan ethyl ester (2) in a esterification reaction using thionylchloride and 
ethanol followed by Pictet-Spengler reaction to obtain ethyl 2,3,4,9-tetrahydro-1-phenyl-1H-
pyrido[3,4-b]indole-3-carboxylate (3) upon reaction with benzaldehydein presence of 
trifluoroacetic acid and dichloro methane as solvent. Continued by oxidation of ethyl 2,3,4,9-
tetrahydro-1-phenyl-1H-pyrido[3,4-b]indole-3-carboxylate (3) with potassium permanganate and 
tetrahydrofuran as solvent to get ethyl-1-phenyl-9H-pyrido[3,4-b]indole-3-carboxylate (4) [37] 
and  key intermediate 9-methyl-1-phenyl-9H-pyrido[3,4-b]indole-3-carboxylic acid (5) was 
obtained by alkaline ester hydrolysis using sodium hydroxide. The carboxylic acid group 
containing key intermediate (5) was further treated with substituted aryl-piperazines (6a-p) in the 
presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and 
hydroxybenzotriazole (HOBt) to obtain the desired products (7a-p) in excellent to good yields 
[38, 39]. 
 
Scheme 1: Reagents and conditions: i) thionylchloride, ethanol, reflux, 30 min, 76 %; ii) benzaldehyde, 
trifluoroaceticacid, DCM, rt, 3 h, 82 %; iii) KMnO4, THF, rt, 24 h, 68 %; iv) 50 % aq. NaOH, reflux, 30 min, 78 %; 
v) EDCI, HOBt, THF, 0 ºC-rt 6 h, 62-82 %. 
 
All the synthesized compounds were characterized by IR, NMR, Mass spectral and elemental 
analysis. IR spectra of the reported compounds showed C=O stretching at 1641 to 1606 cm-1, 
aromatic C-H stretching at 3275 to 3157 cm-1, C-O stretching (methoxy) at 1255 to 1242 cm-1, 
N-O asymmetric stretching at 1319 cm-1 and C-Cl absorption band at 734 to 742 cm-1. 1H NMR 
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spectrum of the compounds showed, characteristic singlet around δ ~8.50 due to position-4 
proton of β-carboline ring, eight piperazine protons appeared as two multiplets around δ value 
4.19 to 4.02 (O=CN(CH2)2) and 3.64 to 2.62 (CN(CH2)2). Piperazine protons were shifted to 
down field (δ ~4.20 and 3.64) on nitro substitution whereas, shifted up field in benzyl derivatives 
(δ ~4.0 and 2.62). Methoxy protons appeared as singlet at δ ~3.80 and aromatic methyl protons 
as singlet at δ ~2.30. In mass spectral analysis, [M+H]+ peak appeared as parent ion peak. 
2.2. Biological evaluation 
2.2.1. Cytotoxicity Evaluation 
Reported (1-phenyl-9H-pyrido[3,4-b]indol-3-yl)(4-phenylpiperazin-1-yl)methanone derivatives 
were initially evaluated for cytotoxicity against HeLa cell lines at 500 µM concentration using an 
Alamar blue assay. Most of these analogues were non-toxic to HeLa cell lines at 500 µM 
concentration. Compounds which showed any significant cytotoxicity against HeLa cells, were 
further evaluated to determine their cytotoxic concentration (CC50) values. 
2.2.2. Anti-leishmanial Screening 
Anti-leishmanial activity of these analogues was determined by evaluating their inhibition 
activity against both promastigote, amastigote forms of Leishmania infantum and Leishmania 
donovani strains. Compounds were screened against promastigote forms of the Leishmania 
strains to determine their effective concentration (EC50) values. Finally, compounds which 
exhibited potent inhibition of promastigote (EC50<20 µM) were further evaluated against 
amastigote forms of respective strain using axenic and intracellular amastigote assay methods. 
Anti-leishmanial drugs miltefosine and pentamidine were used as standards for comparison 
purpose. 
2.2.2.1. Leishmania infantum 
2.2.2.1.1. Anti-promastigote activity 
Promastigote inhibition assay was used to evaluate in-vitro anti-leishmanial activity of these 
titled β-carboline derivatives. Most of these reported β-carboline derivatives displayed 
significant inhibition of L. infantum promastigotes. Among these compounds, 7b, 7d, 7e, 7f and 
7m exhibited potent anti-promastigote activity (EC50 9.63, 9.07, 2.89, 3.35 and 10.70 µM, 
respectively) than standard drugs miltefosine and pentamidine (EC50 8.31 and 12.6 µM). 
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Especially compounds 7e and 7f showed 4 times potent inhibition than standard drugs with better 
selectivity, while compounds 7b, 7d and 7m displayed comparable equal potency as that of 
standard drugs. Compounds 7i, 7j, 7k and 7l displayed significant inhibition of promastigote 
(EC50 15.70, 14.10, 14.90 and 19.80 µM, respectively) and are comparable to standard drugs 
(Table 1). Compounds such as 7c, 7g and 7o displayed moderate inhibitory activity (EC50 36.2, 
33.0and 34.0 µM, respectively) against promastigotes. Structure activity relationship analysis 
emphasized that, electron donating groups, especially methoxy substitution on phenyl ring 
favored the activity, while replacement of phenyl with pyridine and benzyl rings significantly 
decreased the inhibition activity against L. infantum promastigotes. 
2.2.2.1.2. Anti-amastigote activity 
Compounds which displayed significant inhibitory activity (EC50<20 µM) against promastigotes 
(insect stage) were further screened against amastigote forms (human life stage form) to establish 
their activity in the intracellular stage of the parasite. Anti-amastigote activity of selected β-
carboline derivatives was evaluated using axenic amastigote assay method. Axenic amastigotes 
are the amastigotes that are grown in a medium outside host cells that mimic intracellular 
conditions. Axenic amastigotes have the advantage of high similarity with the human parasite 
stage than promastigotes and are commonly used as an easy in-vitro screening method to 
evaluate amastigote inhibition activity.[40] 
Amastigote inhibition assay results suggested that these β-carboline derivatives exhibited potent 
inhibition of L. infantum amastigotes than promastigote forms (Table 1). Especially, compounds 
such as 7b, 7d, 7e, 7f, 7k and 7m exhibited promising anti-amastigote activity with EC50 values 
at uni-micro molar concentration (EC50 6.20, 5.20, 2.80, 4.90, 9.40 and 2.90 µM, respectively). 
These compounds displayed 2-5 times potent inhibition of L. infantum amastigotes than 
promastigotes. Compounds 7i and 7j displayed significant inhibition (EC50 12.20 and 11.30 µM) 
of L. infantum amastigotes and inhibition potency is comparable against both the forms.  
Anti-amastigote activity Structure Activity Relationship (SAR): Among these reported β-
carboline derivatives, un-substituted phenyl derivative 7a showed significant inhibition of L. 
infantum amastigotes. Electron donating methoxy substitution on meta position of phenyl ring 
has considerably increased the anti-amastigote activity as well as reduced the cytotoxicity. 
Substitution of methoxy on ortho-para position of phenyl ring has not affected the activity but 
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decreased the toxicity. Para substitution with methyl group has also not altered the amastigote 
activity. Electron withdrawing chloro, fluoro, nitro group substitution on phenyl ring has 
negatively affected the anti-amastigote activity of these analogues. Although, meta, chloro 
substitution has increased the potency, selectivity index has been decreased to 5.6, due to 
increased cytotoxicity. Di-chloro substitutions at ortho and meta positions of phenyl ring affords 
increased amastigote inhibition activity. More interestingly, additional chloro substitution on 
ortho position marginally increased the activity and vanished the toxicity of the meta chloro 
derivative (7h). SAR study revealed that, meta position is highly responsive, substitution with 
either electron donating and withdrawing group has significantly enhanced anti-amastigote 
potency, but it also increased the cytotoxicity. Interestingly, additional substitution on ortho 
position has reversed the cytotoxicity of these meta derivatives. These results suggested that, 
selective substitutions on ortho / para along with meta substitution (preferably electron donating 
groups) can be explored to develop potent anti-leishmanial agents with good selectivity against 
L. infantum. 
Table 1 In-vitro assay results of the titled compounds against Leishmania infantum 
 
ND – Not Determined; a = CC50 / EC50 
2.2.2.2. Leishmania donovani 
In Leishmania donovani promastigote inhibition assay, compounds 7b, 7d, 7e, 7f, 7i, 7k, 7m and 
7o exhibited potent inhibition (EC50 4.91, 6.32, 4.85, 3.49, 6.98, 3.47, 6.95 and 7.5 µM 
respectively) with good selectivity. These compounds showed equal potency as that of standard 
anti-leishmanial drugs pentamidine and miltefosine (EC50 6.40 and 3.12 µM). Compounds 7c, 7j 
and 7l displayed significant anti-promastigote activity (EC50 12.60 13.20 and 12.80 µM, 
respectively). Compound 7g showed moderate inhibition activity (EC50 38.60 µM) against L. 
donovani promastigotes. Structure activity relationship study suggested that, substitution of 
electron donating group on phenyl ring and electron withdrawing group (chloro and fluoro) on 
ortho position of phenyl ring favored promastigote inhibition (Table 2) activity. 
Compounds displayed significant inhibition of L. donovani promastigotes (EC50 <20 µM) were 
further evaluated for anti-amastigote activity using axenic and intracellular amastigote assay 
methods. Most of these screened analogues displayed significant activity against amastigote 
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forms (Table 2). Especially, compounds 7b, 7c, 7d, 7e, 7f, 7i, 7k, 7m and 7o exhibited potent 
inhibition of axenic amastigotes (EC50 3.30, 6.00, 2.80, 1.90, 2.30, 5.80, 2.80, 5.70 and 5.10 µM, 
respectively) with good selectivity. Especially, compounds 7d, 7e, 7f and 7k showed excellent 
potency against axenic amastigotes. Compounds 7j and 7l showed significant inhibition (EC50 
12.60 and 11.80 µM) of axenic amastigotes with good selectivity. Although, compounds 7a, 7h 
and 7p displayed anti-leishmanial activity, they also showed a lack of selectivity. Structure 
activity relationship studies suggested that, electron donating group especially methoxy 
substitution on phenyl ring enhanced amastigote activity significantly. Methyl group substitution 
has increased axenic amastigote inhibition considerably, more preferably on para position than 
ortho position of phenyl ring. Electron withdrawing group substitution on phenyl ring has 
variable effect on amastigote activity. Ortho substitution on phenyl ring has significantly 
increased the activity, especially fluoro substitution, while para substitution has not affected the 
inhibition activity. Furthermore, replacement of the phenyl ring with a heterocyclic pyridine ring 
favored inhibition of L. donovani axenic, but not the intracellular amastigotes (compare 7a to 
7n). 
However, axenic amastigote assay is one of the most commonly used assay method to determine 
anti-leishmanial activity. Literature suggested that, axenic amastigotes are different from 
intracellular amastigotes in terms of protein expression and drug susceptibility [40, 41]. Hence, 
compounds displaying excellent potency against promastigote and axenic amastigotes were 
further screened against intracellular amastigotes to ensure their activity in the truly relevant 
stage of the parasite in the search of potent anti-leishmanial agents with good selectivity. Intra-
macrophage assay report suggested that, macrophage amastigotes are highly susceptible to these 
β-carboline derivatives. These β-carboline derivatives exhibited similar anti-amastigote activity 
in both the assays with minor variations in potency. Most of these analogues 7b, 7c, 7d, 7e, 7f,7i, 
7k,7m and 7o exhibited potent inhibition of intracellular (EC50 5.70, 9.60, 9.20, 6.90, 8.00, 8.50, 
4.00, 6.40 and 11.90 µM, respectively) amastigotes with good selectivity. Compounds 7j and 7l 
displayed significant inhibition (EC50 22.30 and 21.50 µM) against intracellular amastigotes. 
Compounds 7a, 7h and 7p showed cytotoxicity against HeLa cell lines (CC50 38.10, 18.40 and 
28.90 µM respectively). However, electron withdrawing and donating substitutions has not 
affected the anti-leishmanial activity, instead showed significant effect on cytotoxicity of these 
molecules. SAR studies suggested that, electron donating group substitution favored anti-
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leishmanial activity. Electron withdrawing groups such as chloro and fluoro on ortho substitution 
was recommended for anti-leishmanial activity. Meta substitution with methoxy and chloro has 
increased the activity as well as cytotoxicity, interestingly cytotoxicity has been reduced by 
additional substitution on ortho substitution. Hence, these di-substituent derivatives can be 
studied for further lead optimization process. 
Table 2 In-vitro assay results of the titled compounds against Leishmania donovani 
 
ND- Not Determined; a = CC50 / EC50 
This new series of β-carboline and piperazine hybrid molecules displayed significant anti-
leishamanial activity against both the tested L. infantum and L. donovani strains. Exact 
mechanism of action for their potent anti-leishmanial activity is yet to be identified. We 
hypothesize that known DNA topoisomerases or DNA synthesis inhibition abilities of these β-
carboline derivatives might played a role in their anti-leishmanial activity [42]. Further 
exhaustive studies are required to understand the exact mechanism of action and would be useful 
for further lead optimization of these analogues to develop potential clinical candidates in the 
fight against leishmaniasis. 
3. Conclusion 
In summary, we have successfully applied a molecular hybridization technique to design new 
anti-leishmanial agents. Designed piperazinyl-β-carboline-3-carboxamide derivatives were 
evaluated for inhibition activity against L. infantum and L. donovani. Compounds that exhibited 
significant anti-promastigote activity were further screened against amastigote forms of 
respective species using axenic and intracellular amastigote cell cultures. Among these reported 
analogues, 7b, 7d, 7e, 7f and 7m displayed potent inhibition of both promastigote and amastigote 
forms of L. infantum with good selectivity index. Compounds 7e and 7m showed potent activity 
against both forms of Leishmania, with potency just as good as, and in some case slightly better 
than miltefosine, while still having a workable therapeutic window. These β-carboline 
derivatives were also screened against intracellular amastigotes to ensure that their activity was 
not influenced detrimentally by the issue of the host cell, which might prevent an effective 
concentration getting to the parasite. Compounds 7b, 7d, 7e, 7f, 7i, 7k and 7m were exhibited 
potent activity against both promastigotes and amastigotes of L. donovani with good selectivity. 
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Especially, compound 7k displayed most potent activity against L. donovani and potency was 
comparable with miltefosine and pentamidine. SAR studies revealed that, electron donating 
substituents favored anti-leishmanial activity while electron withdrawing substitution on ortho 
position is recommended for activity. Meta position of phenyl ring is highly responsive, electron 
donating and withdrawing group substitution has significantly enhanced anti-leishmanial activity 
and cytotoxicity. Interestingly, additional substitution on ortho position has reversed the 
cytotoxicity of these meta derivatives. Replacement of phenyl ring has increased cytotoxicity of 
these analogues. Further exhaustive studies are required to understand the exact molecular 
mechanism of action and would be useful in lead optimization studies to develop potential 
clinical candidates to fight against leishmaniasis. 
4. Experimental Protocols 
4.1. Chemistry 
All solvents and reagents purchased from Sigma or Merck companies were used as received 
without further purification. Solvent system used throughout the experimental work for running 
Thin Layer Chromatography (TLC) was Ethyl acetate and Hexane Mixture (6:4) in order to 
monitor the reaction. Column chromatography was performed using silica gel (100-200 mesh, 
SRL, India) as stationary phase, mixture of ethyl acetate and hexane as mobile phase. Melting 
point was determined in open capillary tube on a Precision Buchi B530 (Flawil, Switzerland) 
melting point apparatus containing silicon oil and are uncorrected. IR spectra of the synthesized 
compounds were recorded using FTIR spectrophotometer (Shimadzu IR Prestige 21, India). 1H 
NMR spectra was recorded on a Bruker DPX-400 spectrometer (Bruker India Scientific Pvt. 
Ltd., Mumbai) using TMS as an internal standard (chemical shifts in δ). Elemental analysis was 
performed on Vario EL III M/s Elementar C, H, N and S analyzer (Elementar Analysen systeme 
GmbH, Germany). The ESMS was recorded on MICROMASS Quattro-II LCMS system (Waters 
Corporation, Milford, USA). 
4.2. General procedure for the preparation of 7 
To the stirred solution of 1-phenyl-9H-pyrido[3,4-b]indole-3-carboxylic acid 5 (0.29 g, 0.001 
mol) in dry THF, HOBt (0.16 g, 0.012 mol) and EDC. HCl (0.23 g, 0.012 mol) were added and 
continued stirring for 30 min. To the reaction mixture, substituted phenyl piperazine (6a-p) 
(0.001 mol) was added under ice cold temperature and the reaction mixture was further stirred at 
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room temperature for 6 h. After completion of reaction as monitored by TLC, solvent was 
evaporated under vacuum. Reaction mixture was extracted with ethyl acetate (2 x 20 mL), 
collected organic layer was dried over anhydrous Na2SO4, concentrated under vacuum and 
passed through small bed of silica gel (60-120) using mobile phase (ethyl acetate: hexane; 3:7) to 
obtain analytically pure final product 7. 
(1-phenyl-9H-pyrido[3,4-b]indol-3-yl)(4-phenylpiperazin-1-yl)methanone (7a) 
White Solid; % Yield 74; mp 158-160 °C; IR νmax/cm (KBr): 3157, 1614, 1556, 1489, 738; 1H 
NMR (400 MHz, CDCl3) δ 8.82 (s, 1H), 8.53 (s, 1H), 8.21 (d, J = 7.8 Hz, 1H), 7.64-7.58 (m, 
3H), 7.54-7.52 (m, 3H), 7.48-7.46 (m, 1H), 7.37-7.32 (m, 1H), 7.31-7.26 (m, 2H), 6.95-6.89 (m, 
3H), 4.10-4.01 (m, 4H), 3.23-3.21 (m, 4H); MS m/z 433.4 [M + H]+. 
(1-phenyl-9H-pyrido[3,4-b]indol-3-yl)(4-p-tolylpiperazin-1-yl)methanone (7b) 
White solid; % Yield 74; mp 208-210 °C; IR νmax/cm (KBr): 3228, 1620, 1587, 1490, 1433, 
746; 1H NMR (400 MHz, CDCl3) δ 8.77 (s, 1H), 8.51 (s, 1H), 8.19 (d, J = 7.9 Hz, 1H), 7.98 (d, 
J = 7.2 Hz, 2H), 7.65-7.52 (m, 7H), 7.37 (t, J = 7.3 Hz, 1H), 7.15 (d, J = 7.1 Hz, 2H), 4.15-4.03 
(m, 4H), 3.35-3.26 (m, 4H), 2.32 (s, 3H); MS m/z 447.4 [M + H]+.  
(1-phenyl-9H-pyrido[3,4-b]indol-3-yl)(4-o-tolylpiperazin-1-yl)methanone (7c) 
 White solid; % Yield 68; mp 122-124 °C; IR νmax/cm (KBr): 3201, 1622, 1556, 1490, 1431, 
740; 1H NMR (400 MHz, CDCl3) δ 8.95 (s, 1H), 8.46 (s, 1H), 8.17 (d, J = 7.9 Hz, 1H), 8.05-
7.96 (m, 2H), 7.67-7.55 (m, 4H), 7.52 (t, J = 7.4 Hz, 1H), 7.38-7.34 (m, 1H), 7.27-7.18 (m, 2H), 
7.12-7.00 (m, 2H), 4.10-4.00 (m, 4H), 3.10-3.01 (m, 4H), 2.38 (s, 3H).  
(4-(4-methoxyphenyl)piperazin-1-yl)(1-phenyl-9H-pyrido[3,4-b]indol-3-yl)methanone (7d) 
 White solid; % Yield 80; mp 182-184 °C; IR νmax/cm (KBr): 3234, 1625, 1546, 1510, 1255, 
746; 1H NMR (400 MHz, CDCl3) δ 8.82 (s, 1H), 8.49 (s, 1H), 8.16 (d, J = 7.9 Hz, 1H), 7.95 (d, J 
= 7.2 Hz, 2H), 7.62-7.48 (m, 7H), 7.37-7.32 (m, 1H), 6.88 (d, J = 8.9 Hz, 2H), 4.25-4.10 (m, 
4H), 3.79 (s, 3H), 3.32-3.26 (m, 4H); MS m/z 463.4 [M + H]+. 
(4-(3-methoxyphenyl)piperazin-1-yl)(1-phenyl-9H-pyrido[3,4-b]indol-3-yl)methanone (7e) 
White solid; % Yield 74; mp 118-120 °C; IR νmax/cm (KBr): 3221, 1606, 1536, 1492, 1251, 
741; 1H NMR (400 MHz, CDCl3) δ 8.78 (s, 1H), 8.51 (s, 1H), 8.19 (d, J = 7.9 Hz, 1H), 8.00 (d, 
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J = 7.2 Hz, 2H), 7.65-7.52 (m, 5H), 7.37 (t, J = 7.3 Hz, 1H), 7.22 (t, J = 8.2 Hz, 1H), 6.60-6.58 
(m, 1H), 6.51-6.48 (m, 2H), 4.10-4.06 (m, 4H), 3.82 (s, 3H), 3.37-3.30 (m, 4H). 
(4-(2-methoxyphenyl)piperazin-1-yl)(1-phenyl-9H-pyrido[3,4-b]indol-3-yl)methanone (7f) 
White solid; % Yield 64; mp 110-112 °C; IR νmax/cm (KBr): 3244, 1624, 1558, 1498, 1242, 
740; 1H NMR (400 MHz, CDCl3) δ 8.82 (s, 1H), 8.47 (s, 1H), 8.17 (d, J = 7.9 Hz, 1H), 8.01-
7.98 (m, 2H), 7.64-7.51 (m, 5H), 7.38-7.34 (m, 1H), 7.08-7.04 (m, 1H), 7.01-6.90 (m, 3H), 4.20-
4.10 (m, 4H), 3.91 (s, 3H), 3.25-3.16 (m, 4H). 
(4-(4-chlorophenyl)piperazin-1-yl)(1-phenyl-9H-pyrido[3,4-b]indol-3-yl)methanone (7g) 
White solid; % Yield 76; mp 186-188 °C; IR νmax/cm (KBr): 3203, 1610, 1588, 1481, 738; 1H 
NMR (400 MHz, CDCl3) δ 11.67 (s, 1H), 8.44 (s, 1H), 8.24 (d, J = 7.9 Hz, 1H), 8.10-8.06 (m, 
2H), 7.67-7.60 (m, 5H), 7.30-7.26 (m, 1H), 7.19 (dd, J = 9.8, 6.4 Hz, 2H), 6.94 (d, J = 9.1 Hz, 
2H), 3.99-3.95 (m, 4H), 3.30-3.25 (m, 4H); MS m/z 468.2 [M + H]+, 470.2 [M + H3]+. 
(4-(3-chlorophenyl)piperazin-1-yl)(1-phenyl-9H-pyrido[3,4-b]indol-3-yl)methanone (7h) 
White solid; % Yield 72; mp 138-140 °C; IR νmax/cm (KBr): 3201, 1618, 1558, 1481, 734; 1H 
NMR (400 MHz, CDCl3) δ 8.75 (s, 1H), 8.52 (s, 1H), 8.19 (d, J = 7.9 Hz, 1H), 8.00 (d, J = 7.0 
Hz, 2H), 7.66-7.53 (m, 5H), 7.39-7.35 (m, 1H), 7.21 (t, J = 8.1 Hz, 1H), 6.93 (t, J = 2.1 Hz, 1H), 
6.88-6.82 (m, 2H), 4.12-4.06 (m, 4H), 3.38-3.31 (m, 4H). 
(4-(2-chlorophenyl)piperazin-1-yl)(1-phenyl-9H-pyrido[3,4-b]indol-3-yl)methanone (7i) 
White solid; % Yield 64; mp 108-110 °C; IR νmax/cm (KBr): 3203, 1622, 1546, 1488, 742; 1H 
NMR (400 MHz, CDCl3) δ 8.74 (s, 1H), 8.50 (s, 1H), 8.19 (d, J = 7.9 Hz, 1H), 8.01-7.99 (m, 
2H), 7.65-7.54 (m, 5H), 7.42-7.35 (m, 2H), 7.27-7.24 (m, 1H), 7.09-7.01 (m, 2H), 4.12-4.02 (m, 
4H), 3.24-3.16 (m, 4H). 
(4-(4-nitrophenyl)piperazin-1-yl)(1-phenyl-9H-pyrido[3,4-b]indol-3-yl)methanone (7j) 
Yellow solid; % Yield 62; mp 134-136 °C; IR νmax/cm (KBr): 3184, 1624, 1595, 1489, 1319, 
752; 1H NMR (400 MHz, CDCl3) δ 8.76 (s, 1H), 8.55 (s, 1H), 8.19-8.14 (m, 3H), 7.97 (d, J = 7.1 
Hz, 2H), 7.64-7.52 (m, 5H), 7.36 (t, J = 7.3 Hz, 1H), 6.84 (d, J = 9.4 Hz, 2H), 4.20-4.06 (m, 4H), 
3.64-3.56 (m, 4H). 
(4-(4-fluorophenyl)piperazin-1-yl)(1-phenyl-9H-pyrido[3,4-b]indol-3-yl)methanone (7k) 
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White solid; % Yield 72; mp 178-180 °C; IR νmax/cm (KBr): 3209, 1614, 1550, 1508, 744; 1H 
NMR (400 MHz, CDCl3) δ 8.72 (s, 1H), 8.49 (s, 1H), 8.17 (d, J = 7.9 Hz, 1H), 7.98-7.96 (m, 
2H), 7.63-7.40 (m, 5H), 7.37-7.33 (m, 1H), 7.01-6.89 (m, 4H), 4.09-4.06 (m, 4H), 3.26-3.18 (m, 
4H); MS m/z 451.3 [M + H]+ . 
(4-(2-fluorophenyl)piperazin-1-yl)(1-phenyl-9H-pyrido[3,4-b]indol-3-yl)methanone(7l) 
White solid; % Yield 68; mp 104-106 °C; IR νmax/cm (KBr): 3182, 1610, 1556, 1498, 750; 1H 
NMR (400 MHz, CDCl3) δ 8.80 (s, 1H), 8.50 (s, 1H), 8.18 (d, J = 7.9 Hz, 1H), 8.02-7.98 (m, 
2H), 7.65-7.51 (m, 5H), 7.39-7.35 (m, 1H), 7.12-7.05 (m, 2H), 7.02-6.97 (m, 2H), 4.11-4.10 (m, 
4H), 3.28-3.20 (m, 4H). 
(4-(2,3-dichlorophenyl)piperazin-1-yl)(1-phenyl-9H-pyrido[3,4-b]indol-3-yl)methanone (7m) 
White solid; % Yield 62; mp 124-126 °C; IR νmax/cm (KBr): 3174, 1616, 1562, 1491, 742; 1H 
NMR (400 MHz, CDCl3) δ 8.90 (s, 1H), 8.44 (s, 1H), 8.14 (d, J = 7.9 Hz, 1H), 7.95 (d, J = 7.2 
Hz, 2H), 7.60-7.47 (m, 4H), 7.49 (t, J = 7.4 Hz, 1H), 7.35-7.31 (m, 1H), 7.20-7.14 (m, 2H), 6.96 
(dd, J = 7.5, 2.0 Hz, 1H), 4.07 (m, 4H), 3.19-3.12 (m, 4H). 
(1-phenyl-9H-pyrido[3,4-b]indol-3-yl)(4-(pyridin-4-yl)piperazin-1-yl)methanone (7n) 
Pale yellow solid; % Yield 66; mp 130-132 °C; IR νmax/cm (KBr): 3162, 1641, 1541, 1419; 1H 
NMR (400 MHz, CDCl3) δ 11.70 (s, 1H), 8.47 (s, 1H), 8.26-8.19 (m, 2H), 8.09-8.06 (m, 2H), 
7.69-7.53 (m, 6H), 7.30-7.27 (m, 1H), 6.84 (t, J = 11.7 Hz, 2H), 4.03-3.93 (m, 4H), 3.57-3.51 (m, 
4H). 
(1-phenyl-9H-pyrido[3,4-b]indol-3-yl)(4-(pyridin-2-yl)piperazin-1-yl)methanone (7o) 
Pale yellow solid; % Yield 62; mp 110-112 °C; IR νmax/cm (KBr): 3275, 1635, 1581, 1435, 
734; 1H NMR (400 MHz, CDCl3) δ 8.90 (s, 1H), 8.49 (s, 1H), 8.23 (d, J = 3.6 Hz, 1H), 8.18 (d, J 
= 7.9 Hz, 1H), 7.98 (d, J = 7.1 Hz, 2H), 7.62-7.50 (m, 6H), 7.36 (t, J = 7.3 Hz, 1H), 6.71-6.67 
(m, 2H), 4.07-4.03 (m, 4H), 3.80-3.65 (m, 4H). 
(4-benzylpiperazin-1-yl)(1-phenyl-9H-pyrido[3,4-b]indol-3-yl)methanone (7p) 
White solid; % Yield 72; mp 160-162 °C; IR νmax/cm (KBr): 3174, 1626, 1556, 1487, 1431, 
738; 1H NMR (400 MHz, CDCl3) δ 8.79 (s, 1H), 8.43 (s, 1H), 8.16 (d, J = 7.9 Hz, 1H), 7.96 (d, J 
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= 7.2 Hz, 2H), 7.66-7.47 (m, 5H), 7.35-7.28 (m, 6H), 4.00-3.92 (m, 4H), 3.59 (s, 2H), 2.62-2.20 
(m, 4H); MS m/z 447.6 [M + H]+. 
4.3. Biological Evaluation 
4.3.1. Cytotoxicity assay 
HeLa cell cytotoxicity studies were carried out as described previously [43]. Briefly, the cells 
were cultured in DMEM supplemented with 10% fetal calf serum and 2 mM L-glutamine. Cells 
were plated at initial cell concentration of 2 × 104 cells/well and incubated with the compounds 
for 65 h prior to addition of Alamar Blue solution for a further 5 h. 
4.3.2. Promastigote assay 
L. donovani promastigotes were cultured at 26°C in M199 medium supplemented with 10% 
heat-inactivated fetal calf serum. L. infantum JPCM5 MCAN/ES/98/LLM-87 promastigotes were 
cultured at 26 °C in modified Eagle’s medium (HOMEM) [44]. Parasites were incubated with 
serial dilutions of compounds for 72 h, followed by Alamar blue-based assay as previously 
described [40]. 
4.3.3. Axenic amastigote assay 
L. donovani LdBOB axenic amastigotes or L. infantum clone JPCM5 MCAN/ES/98/LLM-87 
were cultured at 26°C in modified Eagle’s medium (HOMEM; L. infantum) and axenic 
amastigotes were incubated for 72 h with compounds, followed by Alamar blue-based assay as 
previously described [40]. 
4.3.4. Intra macrophage L. donovani (amastigote) assay 
THP-1 (human monocytic leukemia) cells were a kind gift from Dr Susan Wylie (Dundee) and 
maintained in minimal essential medium plus 10% (vol/vol) FBS. An intracellular Leishmania 
assay using LdBOB amastigotes were performed utilizing PMA differentiated THP-1 cells 
infected overnight with axenic amastigotes, prior to compounds being added and incubated for 
further 72 h, subsequent microscopy-based readout was used to determine EC50 values [40]. 
Briefly, THP-1 cells (20,000 per well, 200 µl) were plated into 96 well plates in presence of 10 
nM PMA and incubated at 37 oC in 5% CO2 atmosphere for 75 h. The adhered cells were then 
washed with phosphate buffered saline supplemented with 1 mM CaCl2, 0.5 mM MgCl2, 0.1% 
(w/v) bovine serum albumin and using LdBOB amastigotes added to all wells at a multiplicity of 
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infection of 5 (100,000 amastigotes per well) and incubated for 18 h. Any remaining 
extracellular amastigotes were removed and the adhered cells were washed with the same 
supplemented PBS solution as above. Pre-aliquoted compounds in a serial dilution were added 
from another plate, such that the total well volume was 200 µL and incubated for further 72 h. 
Cells were fixed with 100% methanol, stained with Giemsa and examined microscopically. 
Number of intracellular amastigotes (~200 macrophages per well) were determined and the 
percentage infection was established compared to an untreated control (100%) allowing EC50 
values to be calculated. 
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Table 1 
 
 
 
 
 
Compound 
code 
R 
HeLa  
CC50 (µM) 
L. infantum 
promastigotes 
EC50 (µM) 
S.I.a 
L. infantum 
axenic 
amastigotes EC50 
(µM) 
S.I.a 
7a -C6H5 38.1 ± 1.4 12.5 ± 1.7 3.0 4.5 ±2.1 8.5 
7b -4CH3C6H5 >500 9.63 ± 0.72 >51.9 6.2±0.5 >80.6 
7c -2CH3C6H5 >500 36.2 ± 2.5 >13.8 ND - 
7d -4OCH3C6H5 >500 9.07 ± 0.42 >55.1 5.2 ± 0.3 >96.2 
7e -3OCH3C6H5 205.3 ± 9.6 2.89 ± 0.34 71.0 2.8±0.13 73.3 
7f -2OCH3C6H5 204.8 ± 14.8 3.35 ± 0.25 61.1 4.9 ±0.4 41.8 
7g -4ClC6H5 >500 33.0 ± 1.7 >15.2 ND - 
7h -3ClC6H5 18.4 ± 0.6 15.9 ± 1.4 1.2 3.3±0.4 5.6 
7i -2ClC6H5 >500 15.7 ± 1.5 >31.8 12.2±2.3 >41.0 
7j -4FC6H5 >500 14.1 ± 0.3 >35.5 11.3±0.7 >44.2 
7k -2FC6H5 >500 14.9 ± 0.9 >33.6 9.4±0.8 >53.2 
7l -4NOC6H5 >500 19.8 ± 0.9 >25.5 24.8± 1.7 >20.2 
7m -2,3-ClC6H5 >500 10.7 ± 1.0 >46.7 2.9±0.3 >172.4 
7n -4C5H5N 78.7 ± 4.5 66.7 ± 3.9 1.2 ND - 
7o -2C5H5N >500 34.0 ± 0.9 >14.7 ND - 
7p -CH2C6H5 28.9 ± 1.2 24.3 ± 0.8 1.2 ND - 
Pentamidine - -  8.31 ± 0.18 - 2.7 ± 0.4 - 
Miltefosine - - 12.6±1.1 - 4.8 ± 0.8 - 
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Table 2 
Compound  
code 
HeLa CC50 
(µM) 
L. donovani 
promastigo
tes 
EC50 (µM) 
S.I.a 
L. donovani 
axenic 
amastigotes 
EC50 (µM) 
S.I.a 
L. donovani 
intracellular 
amastigotes 
EC50 (µM) 
S.I.a 
7a 38.1 ± 1.4 16.3 ± 0.9 2.3 12.5±0.3 3.0 7.3±1.4 5.2 
7b >500 4.91 ± 0.38 >101.8 3.3±0.1 >151.5 5.7±0.6 >87.7 
7c >500 12.6 ± 0.9 >39.7 6.0±0.2 >83.3 9.6±2.2 >52.1 
7d >500 6.32 ± 0.59 >79.1 2.8±0.2 >178.6 9.2±1.5 >54.4 
7e 205.3 ± 9.6 4.85 ± 0.28 42.3 1.9±0.1 108.1 6.9±0.4 29.7 
7f 204.8 ± 14.8 3.49 ± 0.18 58.7 2.3±0.1 89.0 8.0±0.7 25.6 
7g >500 38.6 ± 3.5 >12.9 ND - ND - 
7h 18.4 ± 0.6 13.2 ± 0.95 1.4 10.2±0.4 1.8 6.8±2.4 2.7 
7i >500 6.98 ± 0.67 >71.6 5.8±0.3 >86.2 8.5±0.6 >58.8 
7j >500 17.5 ± 1.3 >28.6 12.6±1.1 >39.7 22.3±3.0 >22.4 
7k >500 3.47 ± 0.17 >144.1 2.8±0.1 >178.6 4.0±0.6 >125 
7l >500 12.8 ± 0.7 >39.1 11.8±0.9 >42.4 21.5±2.4 >23.3 
7m >500 6.95 ± 0.57 >71.9 5.7±0.4 >87.7 6.4±0.4 >78.1 
7n 78.7 ± 4.5 68.5 ± 2.9 1.2 ND - ND - 
7o >500 7.5 ± 0.69 >66.7 5.1±0.2 >98.0 11.9±1.6 >42.0 
7p 28.9 ± 1.2 16.4 ± 1.7 1.8 12.6±0.4 2.3 8.8±2.7 3.3 
Pentamidine  - 6.40 ± 0.11 - 1.6 ± 0.1 -  23.7 ± 1.8 -  
Miltefosine  - 3.12±0.16 -  2.8 ± 0.4 -  6.4 ± 0.3 -  
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Design, synthesis and biological evaluation of piperazinyl-β-carboline derivatives as anti-
leishmanial agents 
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Highlights 
• Novel β-carboline derivatives were designed based on molecular hybridization approach 
• Cytotoxicity was evaluated against HeLa cell lines using an Alamar blue method 
• Anti-leishmanial activity was determined against both L. infantum & L. donovani 
• 7e displayed EC50 2.89 & 2.80 µM against L. infantum promastigotes, axenic amastigotes 
• 7k showed EC50 3.47 & 2.80 µM against promastigotes, axenic amastigotes of L. 
donovani 
